Targeted Alpha Therapy, an Emerging Class of Cancer Agents
Top Cited Papers
- 1 December 2018
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (12), 1765-1772
- https://doi.org/10.1001/jamaoncol.2018.4044
Abstract
Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types. Observations Theoretically, the high-energy emission of short-range alpha particles causes complex double-stranded DNA breaks, eliciting cell death. No known resistance mechanism to alpha particles has been reported or scientifically established. The short-range emission of alpha particle radiation confines its cytotoxic effect to cancerous lesions and the surrounding tumor microenvironment while limiting toxic effects to noncancerous tissues. The high level of radiobiological effectiveness of alpha particles, in comparison with beta emissions, requires fewer particle tracks to induce cell death. Clinically effective alpha particle–emitting isotopes for cancer therapy should have a short half-life, which will limit long-term radiation exposure and allow for the production, preparation, and administration of these isotopes for clinical use and application. Radium 223 dichloride is the first-in-class, commercially available targeted alpha therapy approved for the treatment of patients with metastatic castration-resistant prostate cancer with bone metastases. Given the established overall survival benefit conferred by radium 223 for patients with metastatic castration-resistant prostate cancer, several other targeted alpha therapies are being investigated in clinical trials across many tumor types. Conclusions and Relevance Targeted alpha therapy represents an emerging treatment approach and provides for the possibility to bypass mechanisms of acquired resistance in selected tumors. In addition, developing novel radionuclide conjugation strategies may overcome targeting limitations. So far, the clinical success of radium 223 has demonstrated the proof of concept for targeted alpha therapy, and future studies may lead to additional treatment options for many cancer types.Keywords
This publication has 45 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2013
- Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting 227Th-DOTA-p-benzyl-trastuzumabPLOS ONE, 2012
- Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumabEJNMMI Research, 2011
- Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid LeukemiaClinical Cancer Research, 2010
- Therapeutic Radionuclides: Biophysical and Radiobiologic PrinciplesSeminars in Nuclear Medicine, 2008
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- Targeted α-therapy: past, present, future?Dalton Transactions, 2007
- Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancerSupportive Care in Cancer, 2007
- Antibody-guided radiation therapy of cancerCancer and Metastasis Reviews, 2005
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005